Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 and Testosterone Interaction: Monitor | Peptide Database

Compound Profiles ACE-031 Myostatin Inhibitor | Experimental Muscle Growth ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Testosterone

Anabolic-Androgenic Steroid | Primary Male Sex Hormone

Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take ACE-031 with Testosterone?

Yes, but with caution. Both ACE-031 and Testosterone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and Testosterone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between ACE-031 and Testosterone?

Both ACE-031 and Testosterone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and Testosterone?

ACE-031 has a half-life of 12-15 days and Testosterone has a half-life of ~8 days (cypionate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

ACE-031 vs Follistatin: Comparative Research Profiles

Both ACE-031 and Follistatin inhibit myostatin and activin signalling, but through different mechanisms and with different characteristics: Molecular Type Fusion protein (80 kDa) Peptide (3…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

ACE-031 1mg - High-Quality Research Peptide

ACE-031, offered at 1mg, is a high-quality, specialised research peptide developed for advanced scientific exploration in muscle physiology. This product is ideal for laboratory settings where precision and reliability are paramount. Product Name: ACE-031 1mg Catalogue Number: ACE1-024 Molecular Weight: 2956.5 g/mol Purity: 95% Sequence: TBC Form: Lyophilised Solid

Source: uk-peptides.com ↗

ACE-031 and Muscular Dystrophy Research: Myostatin Inhibition and Muscle Mass Biology (UK 2026)

ACE-031 is a fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to an IgG1 Fc region. It acts as a ligand trap, sequestering myostatin and related TGF-β superfamily ligands (activin A, GDF-11) and preventing them from binding to endogenous ActRIIB receptors on muscle cells. The resulting disinhibition of muscle protein synthesis produces profound increases in muscle mass and strength in preclinical models. ACE-031 was developed by Acceleron Pharma specifically as a potential treatment for muscle-wasting diseases, including Duchenne muscular dystrophy (DMD). 🔗 Related Reading: For a comprehensive overview of ACE-031 research, mechanisms, UK sourcing, and safety data, see our ACE-031 UK Complete Research Guide.

Source: peptideslabuk.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 Dosage, Reconstitution & Mixing Trends

See ACE-031 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. ACE-031 (ramatercept) is a soluble activin receptor type IIB-Fc fusion protein engineered to act as a myostatin trap, sequestering myostatin and related TGF-beta family ligands to permit muscle hypertrophy. Acceleron Pharma advanced it into Phase 2 trials in Duchenne muscular dystrophy that were halted on safety grounds. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with ACE-031. 7 ACE-031 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (3 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (5 sessions). The most common dosing frequency is once weekly (1 logged protocols). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides